Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study.
Garcia-Alfonso P, Chaves M, Muñoz A, Salud A, García-Gonzalez M, Grávalos C, Massuti B, González-Flores E, Queralt B, López-Ladrón A, Losa F, Gómez MJ, Oltra A, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Garcia-Alfonso P, et al. Among authors: salud a. BMC Cancer. 2015 Apr 29;15:327. doi: 10.1186/s12885-015-1293-y. BMC Cancer. 2015. PMID: 25925749 Free PMC article. Clinical Trial.
Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer.
Cassinello J, Escudero P, Salud A, Marcos F, Pujol E, Pérez-Carrión R, Colmenarejo A, González del Val R, Valero J, Oruezábal MJ, Guillem V, García I, Arcediano A, Marfà X. Cassinello J, et al. Among authors: salud a. Clin Colorectal Cancer. 2003 Aug;3(2):108-12. doi: 10.3816/CCC.2003.n.017. Clin Colorectal Cancer. 2003. PMID: 12952567 Clinical Trial.
Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer.
Nogué M, Salud A, Batiste-Alentorn E, Saigí E, Losa F, Cirera L, Méndez M, Campos JM, Galan A, Escudero P, Arcusa A, Manzano H, de Mendizábal EV, de Olaguer JP, Boleda M, Guasch I, Vicente P. Nogué M, et al. Among authors: salud a. Eur J Cancer. 2005 Oct;41(15):2241-9. doi: 10.1016/j.ejca.2005.07.013. Eur J Cancer. 2005. PMID: 16214045 Clinical Trial.
Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer.
Roca JM, Alonso V, Pericay C, Escudero P, Salud A, Losa F, López LJ, Guasch I, Méndez M, Quintero-Aldana G, Grande C, Vicente P, Arrivi A, Martin C, Moreno I, García P, Antón I, Constenla M, Yubero A, Cirera L; ACROSS Cooperative Group. Roca JM, et al. Among authors: salud a. Chemotherapy. 2010;56(2):142-6. doi: 10.1159/000313527. Epub 2010 Apr 21. Chemotherapy. 2010. PMID: 20407241 Clinical Trial.
Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study.
Nogué M, Salud A, Vicente P, Arriví A, Roca JM, Losa F, Ponce J, Safont MJ, Guasch I, Moreno I, Ruiz A, Pericay C; AVACROSS Study Group. Nogué M, et al. Among authors: salud a. Oncologist. 2011;16(5):614-20. doi: 10.1634/theoncologist.2010-0285. Epub 2011 Apr 5. Oncologist. 2011. PMID: 21467148 Free PMC article. Clinical Trial.
Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study).
Fernandez-Plana J, Pericay C, Quintero G, Alonso V, Salud A, Mendez M, Salgado M, Saigi E, Cirera L; ACROSS Study Group. Fernandez-Plana J, et al. Among authors: salud a. BMC Cancer. 2014 Nov 22;14:865. doi: 10.1186/1471-2407-14-865. BMC Cancer. 2014. PMID: 25417182 Free PMC article. Clinical Trial.
Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer.
Feliu J, Salud A, Safont MJ, García-Girón C, Aparicio J, Losa F, Bosch C, Escudero P, Casado E, Jorge M, Bohn U, Pérez-Carrión R, Carmona A, Custodio AB, Maurel J. Feliu J, et al. Among authors: salud a. PLoS One. 2015 Jan 20;10(1):e0116527. doi: 10.1371/journal.pone.0116527. eCollection 2015. PLoS One. 2015. PMID: 25602286 Free PMC article.
Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.
Irigoyen A, Gallego J, Guillén Ponce C, Vera R, Iranzo V, Ales I, Arévalo S, Pisa A, Martín M, Salud A, Falcó E, Sáenz A, Manzano Mozo JL, Pulido G, Martínez Galán J, Pazo-Cid R, Rivera F, García García T, Serra O, Fernández Parra EM, Hurtado A, Gómez Reina MJ, López Gomez LJ, Martínez Ortega E, Benavides M, Aranda E; Spanish Cooperative Group of Treatment of Digestive Tumors (TTD). Irigoyen A, et al. Among authors: salud a. Eur J Cancer. 2017 Apr;75:73-82. doi: 10.1016/j.ejca.2016.12.032. Epub 2017 Mar 7. Eur J Cancer. 2017. PMID: 28222309 Clinical Trial.
101 results